<?xml version="1.0" encoding="UTF-8"?>
<p>Hypertensive control animals displayed significant decreases in the glutathione levels in the aorta (29.51%, 
 <italic>p</italic> &lt; 0.001), in the heart (34.46%, 
 <italic>p</italic> &lt; 0.001), and in the kidney (29.11%, 
 <italic>p</italic> &lt; 0.001) compared to the normotensive control group (
 <xref ref-type="fig" rid="fig1">Figure 1(d)</xref>). The animals treated with the extract dose 200 mg/kg significantly mitigated this decrease in the kidney (27.14%, 
 <italic>p</italic> &lt; 0.01, compared to hypertensive rats), while the animals treated with the dose 100 mg/kg mitigated the decrease in the aorta (
 <italic>p</italic> &lt; 0.01) and in the heart (
 <italic>p</italic> &lt; 0.001) (
 <xref ref-type="fig" rid="fig1">Figure 1(d)</xref>). Captopril treatment also mitigated the decrease in reduced glutathione levels in the aorta (106.60%, 
 <italic>p</italic> &lt; 0.001) and in the kidney (28.07%, 
 <italic>p</italic> &lt; 0.01) (
 <xref ref-type="fig" rid="fig1">Figure 1(d)</xref>).
</p>
